Combined pharmacotherapy
ApprovedSmall molecule
Combined pharmacotherapy is one of 28 small molecule programs targeting Overactive Bladder. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Botox
AbbViePhase 3
GSK1358820
GSKPhase 3
Tolterodine PR
PfizerPhase 3
Oxybutynin Chloride
Mylan Pharmaceuticals IncPhase 3
Vesicare
AstellasPhase 3
Combined pharmacotherapy
MMackay Memorial Hospital
Approved
YM178
AstellasPhase 3
SPM 907
PfizerPhase 3
Onabotulinumtoxina 100 UNT
SStanford University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Combined pharmacotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMackay Memorial Hospital